Henlius Finds Global Partner For Ophthalmic Bevacizumab
Strikes Deal With Essex Bio-Technology For Biosimilar Avastin Rival
Shanghai Henlius Biotech has struck a co-development and licensing deal with fellow Chinese firm Essexor biosimilar bevacizumab to treat ophthalmic diseases.
You may also be interested in...
Chinese firms Shanghai Henlius Biotech and Essex Bio-Technology have announced a key milestone in their Chinese Phase I clinical study for the HLX04-O biosimilar bevacizumab candidate to treat wet age-related macular degeneration.
Henlius has announced plans to seeing its sales shoot up in 2020 based on three new launches.
Shanghai Henlius Biotech is planning to move forward with wet AMD trials for its bevacizumab biosimilar rival to Avastin following a nod from the US FDA.